Your browser doesn't support javascript.
loading
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence.
Cun, Wendy Y; Keller, Paul A; Pyne, Stephen G.
Affiliation
  • Cun WY; School of Chemistry and Molecular Science, Molecular Horizons Institute, University of Wollongong, Wollongong, NSW 2522, Australia.
  • Keller PA; School of Chemistry and Molecular Science, Molecular Horizons Institute, University of Wollongong, Wollongong, NSW 2522, Australia.
  • Pyne SG; School of Chemistry and Molecular Science, Molecular Horizons Institute, University of Wollongong, Wollongong, NSW 2522, Australia.
Microorganisms ; 12(6)2024 Jun 15.
Article de En | MEDLINE | ID: mdl-38930588
ABSTRACT
Clostridioides difficile is a Gram-positive, spore-forming anaerobic bacterial pathogen that causes severe gastrointestinal infection in humans. This review provides background information on C. difficile infection and the pathogenesis and toxigenicity of C. difficile. The risk factors, causes, and the problem of recurrence of disease and current therapeutic treatments are also discussed. Recent therapeutic developments are reviewed including small molecules that inhibit toxin formation, disrupt the cell membrane, inhibit the sporulation process, and activate the host immune system in cells. Other treatments discussed include faecal microbiota treatment, antibody-based immunotherapies, probiotics, vaccines, and violet-blue light disinfection.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Microorganisms Année: 2024 Type de document: Article Pays d'affiliation: Australie Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Microorganisms Année: 2024 Type de document: Article Pays d'affiliation: Australie Pays de publication: Suisse